Why Improving Sleep Matters More Than Any Supplement For Brain Health
Quick Read Your brain has a nightly cleaning system called the glymphatic system that removes toxic waste proteins during deep
Subscribe to the distribution list, to get regular updates on supplement research for health,
🧠 NeuroBright Our evidence-based brain supplement formulated from 1.7M research papers
Mild cognitive impairment is a grey zone between normal age-related memory changes and dementia, and it may be an opportunity to slow decline before serious neurodegeneration takes hold. Research shows that several supplements have modest but real benefits for people with MCI, supported by multiple systematic reviews.
Omega-3 fatty acids (DHA and EPA) show the most consistent evidence across nearly 27,000 participants, helping support brain cell membranes and reducing inflammation. B vitamins, vitamin D and probiotics also show positive signals in the research. Combination approaches, which provide multiple nutrients together rather than single supplements in isolation, consistently outperform individual nutrients. Pycnogenol, an extract from French maritime pine bark, ranked highest among botanical interventions tested.
However, studies are often small, use different methods, and don’t yet definitively prove that supplements prevent the progression from MCI to full dementia. The evidence is promising enough to justify daily omega-3s, B vitamins and vitamin D as safe, low-risk interventions, but they work best alongside good sleep, physical activity and a healthy diet, not as replacements for these foundations.
Verdict: Several supplements show modest but real benefits for mild cognitive impairment when taken together, with omega-3s, B vitamins and vitamin D representing the clearest evidence, though none are a substitute for healthy lifestyle habits.
What if the window between “a bit forgetful” and full dementia was actually an opportunity, not just a warning sign? Most people experience mild cognitive impairment (MCI) as a source of quiet dread: the misplaced keys, the word that won’t come, the sense that something has shifted. But here’s a different way to look at it. MCI is a stage. It is not a verdict. And for researchers around the world, it has become one of the most intensively studied intervention windows in all of brain science. The question isn’t just “what’s going wrong?”, it’s “what can we actually do about it?” Vitacuity has analysed over 1.77 million research papers and selected the most relevant for this topic. What follows is an honest account of what the science currently shows, not what we wish it showed, not what supplement companies want you to believe, but what the evidence, fairly read, actually supports.
Before we get to the supplements, it helps to understand what we’re talking about. Mild cognitive impairment sits in a grey zone between normal age-related memory changes and dementia. People with MCI notice real cognitive changes, usually in memory, but sometimes in attention, language or processing speed, but these changes don’t yet significantly interfere with daily life [7].
What makes MCI so significant is what it can become. For many people, it is the earliest detectable stage of Alzheimer’s disease, what researchers call the “prodromal” phase [9]. This is precisely why it has attracted so much nutritional research: if you can intervene here, before widespread neurodegeneration takes hold, you might be able to slow or even alter the trajectory. The neuronal membranes and synaptic connections that support memory and cognition are constantly being remodelled, and they depend on dietary raw materials to do it [11]. That biological reality is the foundation of the entire nutritional intervention field.
The mechanisms being explored centre on several interconnected processes: reducing neuroinflammation, protecting neurons from oxidative stress, supporting the building of healthy neuronal membranes, and ensuring the brain has adequate levels of nutrients it cannot synthesise in sufficient quantities on its own [6].
If there is one nutritional intervention that appears most consistently across the MCI literature, it is omega-3 fatty acids, specifically the long-chain forms DHA (docosahexaenoic acid) and EPA (eicosapentaenoic acid).
A 2025 overview of systematic reviews covering 14 randomised controlled trials and 26,881 participants found a statistically significant, if modest, improvement in cognitive scores (measured by the MMSE, the standard global cognition test) with omega-3 supplementation, effect size 0.16 (95% CI: 0.01–0.32) [3]. That’s not a dramatic number, but it is consistent. The review noted moderate heterogeneity across studies, meaning results varied somewhat, which is worth acknowledging honestly.
A 2024 systematic review and meta-analysis looking specifically at elderly people with MCI found that n-3 PUFA supplementation was beneficial for delaying cognitive decline in this population [2]. And a 2019 systematic review of 14 RCTs found that 10 out of 14 showed positive outcomes on at least one domain of cognitive function, working memory, executive function, verbal memory, short-term memory, and perceptual speed among them [15].
Why might omega-3s help? The brain is roughly 60% fat by dry weight, and DHA is particularly concentrated in neuronal membranes. Adequate DHA supports membrane fluidity, the ease with which signals pass between neurons. EPA has potent anti-inflammatory properties. In people with MCI, levels of both nutrients have been found to be lower than in cognitively healthy individuals [14]. The biological rationale is solid.
The 2024 CARES trial (Cognitive impAiRmEnt Study) gave individuals with clinically confirmed MCI a combination of omega-3s, carotenoids and vitamin E for 12 months. Those in the active intervention group showed improvements in global cognition and episodic memory compared to placebo, alongside measurable increases in blood levels of the nutrients [14].
Evidence grade: Promising to strong. Multiple systematic reviews and RCTs point consistently in the same direction. Effect sizes are modest but real. The most recent and largest overview covers nearly 27,000 participants.
B vitamins, particularly folate (B9), B12 and B6, are frequently cited in cognitive decline research, and the MCI literature shows some genuine positive signals, with an important caveat.
Multiple systematic reviews have found B vitamins to be among the more consistently positive nutritional interventions for people with MCI. A 2023 systematic review of reviews found that reviews were “mostly positive” for B vitamins, drawing on 12 primary studies [7]. A 2018 systematic review found particular improvements in memory from folic acid supplementation in two separate trials (n=266 and n=180 respectively) [8].
Here is the important nuance, though, and this is one of the most interesting findings in the entire field. A 2024 systematic review found that B vitamin supplementation showed positive effects on cognitive outcomes only in non-aspirin users who also had high omega-3 fatty acid plasma levels [1]. In other words, B vitamins may not work in isolation, their effect appears to depend on the broader nutritional and pharmaceutical context of the individual. This is not a reason to dismiss B vitamins; it is a reason to think about them as part of an integrated approach rather than a standalone silver bullet.
Why would omega-3 levels matter for B vitamin effectiveness? The likely mechanism involves homocysteine, a compound that rises when B vitamin status is poor and that is directly toxic to neurons. B vitamins (particularly B12 and folate) are essential for converting homocysteine into harmless compounds. But this conversion process may also depend on adequate fatty acid status. The interaction between these nutrient systems is an active area of research [1][7].
Evidence grade: Promising. Positive signals across multiple reviews, but conditional, benefits appear most pronounced when omega-3 levels are also adequate, and some studies show genotypic differences in response. Water-soluble vitamins, including all B vitamins, are excreted in urine when taken in excess, supplementation is safe and practical as a daily default.
Vitamin D appears in the cognitive decline literature with increasing frequency, and the 2024 systematic review of 33 primary studies identified it as one of three interventions most likely to reduce cognitive decline, alongside probiotics and omega-3s [1].
The mechanism is plausible: vitamin D receptors are found throughout the brain, including in the hippocampus, the region most associated with memory formation. Vitamin D has anti-inflammatory and neuroprotective properties, and deficiency is extraordinarily common in older adults, particularly in northern latitudes like the UK [1][7].
A 2023 systematic review of reviews noted that a small number of studies suggested vitamin D may improve individual cognitive subdomains in people with MCI, though the review was careful to note more studies are needed [7].
Evidence grade: Promising. The biological rationale is strong, vitamin D deficiency is highly prevalent, and the direction of findings in the MCI literature is positive. Toxicity at standard supplementation doses (1,000–4,000 IU daily) is very rare and requires sustained mega-dosing to occur. Deficiency is far more common and far more harmful than excess. Supplementing makes practical sense, particularly in the UK.
One of the more surprising findings in recent MCI research is the repeated appearance of probiotics as a potentially beneficial intervention. The gut-brain axis, the communication network between intestinal bacteria and the central nervous system, has become a legitimate area of neuroscience rather than a fringe theory.
The 2024 systematic review of 33 primary studies identified probiotic supplementation as one of three interventions most likely to reduce cognitive decline in older adults [1]. The 2023 systematic review of reviews found reviews were “mostly positive” for probiotics, drawing on four primary studies [7].
The proposed mechanism involves the gut microbiome’s influence on neuroinflammation, a key driver of cognitive decline. Gut bacteria produce compounds that can cross the blood-brain barrier and influence brain chemistry. Dysbiosis (an imbalanced gut microbiome) has been associated with increased neuroinflammation [1].
Evidence grade: Promising but early. The direction of findings is positive and the mechanism is biologically credible, but the number of high-quality RCTs specifically in MCI populations is still relatively small. This is an area to watch carefully.
A 2025 network meta-analysis, one of the most methodologically rigorous designs for comparing multiple interventions simultaneously, evaluated 18 botanical drug interventions across 19 trials involving 4,956 participants [4].
The standout finding: Pycnogenol (a standardised extract from French maritime pine bark) showed the most significant effect on cognitive function, ranking first for both cognitive performance (SUCRA: 98.8%) and daily living activities (SUCRA: 100%) among all 18 botanical interventions tested. For psychological wellbeing, Cosmos caudatus (a herb used in traditional Southeast Asian medicine) ranked first [4].
Pycnogenol is thought to work through its powerful antioxidant and anti-inflammatory properties, improving cerebrovascular blood flow and reducing oxidative stress in neuronal tissue [4].
It’s important to be clear about what a network meta-analysis tells us, it synthesises the available evidence to rank interventions against each other, but the quality of that ranking is only as good as the underlying trials. The authors noted heterogeneity across studies and called for cautious interpretation. Ginkgo biloba, one of the most widely used herbal supplements for cognition globally [6][8], did not show significant effects on progression from MCI to dementia in a large trial (n=482) reviewed in 2018 [8], though it continues to appear in the literature as a vasodilator with potential effects on cerebral blood flow [6].
Evidence grade: Promising for Pycnogenol, based on the 2025 network meta-analysis. Conflicted for Ginkgo biloba, some positive signals on blood flow but no proven effect on MCI-to-dementia progression.
One of the most intellectually honest findings in the MCI literature is that single-nutrient studies frequently disappoint, while multinutrient approaches show more consistent benefits. This makes biological sense: the brain doesn’t run on one nutrient.
Souvenaid is a medically developed nutritional drink containing a specific combination of omega-3 fatty acids, uridine, choline, B vitamins, vitamin C, vitamin E and selenium. It was designed specifically to support the formation and function of neuronal membranes and synapses [9][11].
A 2019 expert consensus review found that clinical trials showed improved memory performance in patients with mild Alzheimer’s disease, and that Souvenaid should be considered for some patients with MCI due to AD [9]. The 2014 clinical data review noted that RCTs showed improved memory performance in mild AD, with multinutrient strategies outperforming single-agent approaches [11]. A 2023 systematic review found that Souvenaid reduced cognitive decline in a single trial of fewer than 500 participants [7].
A 2025 RCT (107 participants, mean age 63, 12-month duration) tested whey protein powder enriched with milk fat globule membrane (MFGM), taurine and B vitamins in people with MCI. The active group showed significantly greater improvement in MoCA (global cognition) scores compared to placebo, mean difference of 1.81 points (95% CI: 0.32–3.30). Processing speed (Digit Symbol Substitution Test) also improved significantly, with a mean between-group difference of 2.72 points [5].
The CARES trial similarly used a combination of omega-3s, carotenoids and vitamin E, finding improvements in global cognition and episodic memory in MCI patients after 12 months [14].
Evidence grade: Promising for multinutrient combinations. The pattern across studies consistently suggests that combinations outperform individual nutrients.
The honest answer to “which supplement should I take for MCI?” is: we don’t fully know yet, and the research has significant limitations that we want to be transparent about.
Heterogeneity is the central problem. Study populations, dosages, durations, cognitive tests used, and definitions of MCI vary enormously across trials. This makes direct comparison extremely difficult and means that effect sizes from meta-analyses should be read with appropriate caution [1][7][8].
Most individual studies are small. Many of the trials underpinning the positive findings had fewer than 100–200 participants and ran for under 12 months. Cognitive decline is a slow process, we need longer studies with larger samples [7][8][12].
We don’t know what works for whom. There appear to be important individual differences in response, including genotypic differences in B vitamin metabolism and interactions between nutrients (for example, B vitamins appearing to work best when omega-3 levels are also high) [1]. Personalised nutrition for brain health is an aspirational goal, not yet a clinical reality.
The conversion question remains unanswered. The most important clinical question, does nutritional supplementation reduce the conversion rate from MCI to dementia?, remains insufficiently answered. Vitamin E (n=516), ginkgo biloba (n=482) and Fortasyn Connect (n=311) all showed no significant effect on this endpoint in large trials [8]. Improving cognitive test scores is not the same as preventing dementia.
Probiotic research in MCI is early. The positive signals are there but the number of high-quality RCTs in this specific population is still small [7].
Safety reporting is inconsistent. The 2025 botanical network meta-analysis noted that adverse event reporting was inconsistent across studies, a genuine limitation when trying to assess the full picture [4].
Here is what a sensible, well-informed person should actually do with this evidence.
Omega-3s (DHA + EPA) are the clearest starting point. The evidence across multiple systematic reviews, including one covering nearly 27,000 participants, points consistently in a positive direction [2][3][15]. The effect sizes are modest, not miraculous, but they are real and they are consistent. A daily omega-3 supplement providing meaningful doses of DHA and EPA is supported by the evidence and is low risk. If you eat oily fish two or three times a week you may already be getting some benefit from diet, but most people in the UK do not eat enough.
B vitamins are worth taking, but think of them as part of the system, not a standalone. They work best when omega-3 levels are also adequate [1]. Water-soluble B vitamins are excreted in urine when taken in excess, they are safe to supplement daily without testing. Take them alongside omega-3s.
Vitamin D is an easy win. Deficiency is common, particularly in the UK. The brain has vitamin D receptors for a reason. The risk of supplementing at 1,000–2,000 IU daily is negligible. The risk of deficiency is real and measurable. Supplement confidently.
A multinutrient approach makes more biological sense than single-nutrient thinking. The best-performing trials in the MCI literature used combinations, not individual nutrients in isolation [5][9][14]. Think of it as providing the brain with a full toolkit, not just one tool.
Pycnogenol is interesting and worth attention. The 2025 network meta-analysis gave it the strongest ranking of any botanical intervention for cognitive function in MCI [4]. It’s not a definitive verdict, but if you’re drawn to botanical approaches, this is where the current evidence points.
Probiotics are worth considering. The gut-brain connection is real and the signals in the MCI literature are positive [1][7]. A good quality daily probiotic is low risk, low cost and sits comfortably alongside the interventions above.
None of this replaces lifestyle. The research consistently frames supplementation as a complement to, not a substitute for, good sleep, physical activity, cognitive engagement and a Mediterranean-style diet [3][9]. Supplements fill nutritional gaps; they don’t compensate for fundamentally poor lifestyle foundations.
The practical summary: omega-3s daily, B complex daily, vitamin D daily, consider a multinutrient approach or probiotic, and stay honest with yourself about how far the evidence currently reaches. We know more than we did. We don’t know everything yet. That combination of genuine optimism and honest humility is, we think, exactly the right place to stand.
[1] Supplementation and Mitigating Cognitive Decline in Older Adults With or Without Mild Cognitive Impairment or Dementia: A Systematic Review (2024). DOI: 10.3390/nu16203567 | https://pubmed.ncbi.nlm.nih.gov/39458561/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11509913/
[2] N-3 Polyunsaturated Fatty Acids in Elderly with Mild Cognitive Impairment: A Systemic Review and Meta-Analysis (2024). https://pubmed.ncbi.nlm.nih.gov/36776054/
[3] Omega-3 Polyunsaturated Fatty Acids and Cognitive Decline in Adults with Non-Dementia or Mild Cognitive Impairment: An Overview of Systematic Reviews (2025). DOI: 10.3390/nu17183002 | https://pubmed.ncbi.nlm.nih.gov/41010527/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12472900/
[4] Comparative efficacy and safety of botanical drugs for mild cognitive impairment: a systematic review and network meta-analysis (2025). DOI: 10.3389/fphar.2025.1657169 | https://pubmed.ncbi.nlm.nih.gov/41333026/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12665759/
[5] Effect of a 12-mo intervention with whey protein powder on cognitive function in older adults with mild cognitive impairment: a randomized controlled trial (2025). DOI: 10.1016/j.ajcnut.2024.11.019 | https://pubmed.ncbi.nlm.nih.gov/39571910/
[6] Dietary supplements for cognitive impairment (2017). https://pubmed.ncbi.nlm.nih.gov/29171642/
[7] Dietary pattern, food, and nutritional supplement effects on cognitive outcomes in mild cognitive impairment: a systematic review of previous reviews (2023). DOI: 10.1093/nutrit/nuad013 | https://pubmed.ncbi.nlm.nih.gov/37027832/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563860/
[8] Effect of dietary interventions in mild cognitive impairment: a systematic review (2018). DOI: 10.1017/S0007114518002945 | https://pubmed.ncbi.nlm.nih.gov/30409231/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679717/
[9] Souvenaid in the management of mild cognitive impairment: an expert consensus opinion (2019). DOI: 10.1186/s13195-019-0528-6 | https://pubmed.ncbi.nlm.nih.gov/31421681/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698334/
[10] Activities, bioavailability, and metabolism of lipids from structural membranes and oils: Promising research on mild cognitive impairment (2018). https://pubmed.ncbi.nlm.nih.gov/30016644/
[11] Rationale and clinical data supporting nutritional intervention in Alzheimer’s disease (2014). https://pubmed.ncbi.nlm.nih.gov/24635394/
[12] Treatment for mild cognitive impairment: systematic review (2013). https://pubmed.ncbi.nlm.nih.gov/24085737/
[13] A systematic review of the safety and efficacy on cognitive function of herbal and nutritional medicines in older adults with and without subjective cognitive impairment (2023). DOI: 10.1186/s13643-023-02301-6 | https://pubmed.ncbi.nlm.nih.gov/37592293/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10433666/
[14] Targeted Nutritional Intervention for Patients with Mild Cognitive Impairment: The Cognitive impAiRmEnt Study (CARES) Trial 1 (2020). DOI: 10.3390/jpm10020043 | https://pubmed.ncbi.nlm.nih.gov/32466168/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354621/
[15] Omega-3 fatty acids and cognitive decline: a systematic review (2019). DOI: 10.20960/nh.02496 | https://pubmed.ncbi.nlm.nih.gov/31215788/
This article is for informational purposes only and does not constitute medical advice. Food supplements should not be used as a substitute for a varied and balanced diet and healthy lifestyle. If you are pregnant, breastfeeding, taking medication or have a medical condition, consult your doctor before taking any supplement. These statements have not been evaluated by the Food and Drug Administration (FDA) or the Medicines and Healthcare products Regulatory Agency (MHRA). This product is not intended to diagnose, treat, cure, or prevent any disease.
Quick Read Your brain has a nightly cleaning system called the glymphatic system that removes toxic waste proteins during deep
Quick Read Your gut bacteria may play a direct role in Alzheimer’s disease risk. Trillions of microbes in your digestive
